Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Three buys and a bail: AbbVie, Eli Lilly, Humana and Moderna
02:25pm, Friday, 28'th Oct 2022
Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three stocks Sanchez is interested in buying and one the strategist is bailing on.
AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View
02:18pm, Friday, 28'th Oct 2022
AbbVie's earnings (ABBV) beat estimates for third-quarter 2022, while sales miss the same. Shares drop in pre-market trading after it narrows down its full-year earnings guidance.
The 7 Most Popular Dividend Stocks Ranked from Biggest to Smallest
02:17pm, Friday, 28'th Oct 2022
This article will give you seven of the most popular dividend stocks ranked from the largest market cap to the smallest. Dividend stocks have a place in every investor's portfolio.
AbbVie Inc. (ABBV) Q3 2022 Earnings Call Transcript
12:23pm, Friday, 28'th Oct 2022
AbbVie Inc. (NYSE:ABBV ) Q3 2022 Earnings Conference Call October 28, 2022 9:00 AM ET Company Participants Liz Shea – Vice President-Investor Relations Rick Gonzalez – Chairman of the Board and Ch
AbbVie narrows guidance for 2022
08:02am, Friday, 28'th Oct 2022
Shares of AbbVie Inc. ABBV, +0.65% fell 2.9% in premarket trading on Friday after the company trimmed guidance for adjusted earnings per share for the year. AbbVie had earnings of $3.9 billion, or $2.
Pfizer Earnings Preview: Growth & Diversification is Key
09:04pm, Thursday, 27'th Oct 2022
Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely o
AbbVie Q3 Preview: Can Shares Continue Their Run?
05:18pm, Thursday, 27'th Oct 2022
AbbVie shares have been a bright spot in a dim market year-to-date, up a double-digit 17% and easily crushing the S&P 500's performance.
Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?
02:18pm, Wednesday, 26'th Oct 2022
AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.
2 Monster Stocks to Buy Without Any Hesitation
05:30am, Wednesday, 26'th Oct 2022
These stocks are crushing the bear market.
3 Stocks to Avoid This Week
08:10am, Monday, 24'th Oct 2022
These investments seem pretty vulnerable right now.
AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting
07:00am, Monday, 24'th Oct 2022
Data illustrates AbbVie's commitment to providing research and innovative solutions that support patients with high disease burden and unmet need Oral presentations address treatment of moderate to se
3 Healthcare Stocks That Are Too Cheap to Ignore
09:45am, Saturday, 22'nd Oct 2022
They all offer attractive dividends, too.
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition
01:33pm, Friday, 21'st Oct 2022
AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.
AbbVie: The Investor's Trifecta
07:05am, Friday, 21'st Oct 2022
It is well-known that AbbVie loses its US patent protection for Humira in 2023. Humira international sales have fallen sharply after already losing patent protection and the same will be expected in t
Which Stock Is More Likely to Double Your Money First: Moderna or AbbVie?
05:23am, Friday, 21'st Oct 2022
Both companies are developing new drugs but that's where the similarities stop.
